MIT Technology ReviewA Year After Approval, Gene-Therapy Cure Gets Its First CustomerMIT Technology ReviewGene therapy has been widely explored in experimental medical studies, but its commercial potential is largely untested. Prior to now, only a sing… Continue reading
MIT Technology ReviewA Year After Approval, Gene-Therapy Cure Gets Its First CustomerMIT Technology ReviewGene therapy has been widely explored in experimental medical studies, but its commercial potential is largely untested. Prior to now, only a sing… Continue reading
The Scientist |
New Gene Therapy Shrinks Aggressive Tumors in Mice
The Scientist A CRISPR-based gene therapy that targets cancerous fusion genes—hybrid genes that are formed when two previously distinct genes join together—shrinks aggressive forms of liver and prostate cancers in mice. The approach could be developed to address … From theory to therapyLab News Gene Editing Improves Prostate Cancer Survival, Study in Mice ShowsProstate Cancer News Today |
TIME |
How Scientists Think CRISPR Will Change Medicine
TIME With the advent of CRISPR, a new way to edit DNA, the field of genomic technology has never been more exciting. The implications have yet to be seen, but scientists could theoretically snip out a person’s genetic risk for disease. But it’s also never … |
Sacramento Bee |
California stem cell agency president steps down as worries mount …
Sacramento Bee California’s $3 billion stem cell agency, which is nearing the end of its financial life, announced Tuesday it is losing its president as the agency enters what some … CA Stem Cell Agency Chief Randy Mills to Leave After Three Years …Xconomy CIRM — California’s stem cell research funding agency — to lose …San Francisco Business Times |
|
Therapy Focus: Immunotherapy Crowds Bladder Cancer Space
Seeking Alpha Roche’s (OTCQX:RHHBY, OTCQX:RHHBF) Tecentriq is the one to beat after cementing a win in first line last month – the first immunotherapy to do so. Bristol-Myers Squibb’s (NYSE:BMY) Opdivo is approved for second line, while Merck’s (NYSE:MRK) … |